These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 36012331)

  • 1. FAK-Mediated Signaling Controls Amyloid Beta Overload, Learning and Memory Deficits in a Mouse Model of Alzheimer's Disease.
    Saleh B; Srikanth KD; Sneh T; Yue L; Pelech S; Elliott E; Gil-Henn H
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ca2+-permeable TRPV1 pain receptor knockout rescues memory deficits and reduces amyloid-β and tau in a mouse model of Alzheimer's disease.
    Kim J; Lee S; Kim J; Ham S; Park JHY; Han S; Jung YK; Shim I; Han JS; Lee KW; Kim J
    Hum Mol Genet; 2020 Jan; 29(2):228-237. PubMed ID: 31814000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease.
    Lachén-Montes M; González-Morales A; de Morentin XM; Pérez-Valderrama E; Ausín K; Zelaya MV; Serna A; Aso E; Ferrer I; Fernández-Irigoyen J; Santamaría E
    J Proteomics; 2016 Oct; 148():149-58. PubMed ID: 27498392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease.
    Shen Y; Hua L; Yeh CK; Shen L; Ying M; Zhang Z; Liu G; Li S; Chen S; Chen X; Yang X
    Theranostics; 2020; 10(25):11794-11819. PubMed ID: 33052247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease.
    Yang JT; Wang ZJ; Cai HY; Yuan L; Hu MM; Wu MN; Qi JS
    Neurosci Bull; 2018 Oct; 34(5):736-746. PubMed ID: 30099679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.
    Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA
    J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.
    Imamura T; Yanagihara YT; Ohyagi Y; Nakamura N; Iinuma KM; Yamasaki R; Asai H; Maeda M; Murakami K; Irie K; Kira JI
    Neurobiol Dis; 2020 Apr; 137():104739. PubMed ID: 31927145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.
    Dumont M; Stack C; Elipenahli C; Jainuddin S; Launay N; Gerges M; Starkova N; Starkov AA; Calingasan NY; Tampellini D; Pujol A; Beal MF
    FASEB J; 2014 Apr; 28(4):1745-55. PubMed ID: 24398293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671NL)/PSEN1(Δexon9) mouse models identifies shared features with human Alzheimer's brain molecular pathology.
    Readhead B; Haure-Mirande JV; Zhang B; Haroutunian V; Gandy S; Schadt EE; Dudley JT; Ehrlich ME
    Mol Psychiatry; 2016 Aug; 21(8):1099-111. PubMed ID: 26552589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease.
    Martínez-Drudis L; Sheta R; Pellegrinato R; Loukili S; Tremblay C; Calon F; Rivest S; Oueslati A
    Neurobiol Dis; 2022 Oct; 172():105833. PubMed ID: 35905928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Li JG; Praticò D
    PLoS One; 2013; 8(8):e70991. PubMed ID: 23951061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
    Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
    J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression.
    Cole AR; Noble W; van Aalten L; Plattner F; Meimaridou R; Hogan D; Taylor M; LaFrancois J; Gunn-Moore F; Verkhratsky A; Oddo S; LaFerla F; Giese KP; Dineley KT; Duff K; Richardson JC; Yan SD; Hanger DP; Allan SM; Sutherland C
    J Neurochem; 2007 Nov; 103(3):1132-44. PubMed ID: 17683481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology.
    Rothman SM; Tanis KQ; Gandhi P; Malkov V; Marcus J; Pearson M; Stevens R; Gilliland J; Ware C; Mahadomrongkul V; O'Loughlin E; Zeballos G; Smith R; Howell BJ; Klappenbach J; Kennedy M; Mirescu C
    J Neuroinflammation; 2018 Sep; 15(1):256. PubMed ID: 30189875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice.
    Van der Jeugd A; Parra-Damas A; Baeta-Corral R; Soto-Faguás CM; Ahmed T; LaFerla FM; Giménez-Llort L; D'Hooge R; Saura CA
    Sci Rep; 2018 Apr; 8(1):6431. PubMed ID: 29691439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ.
    Ittner A; Asih PR; Tan ARP; Prikas E; Bertz J; Stefanoska K; Lin Y; Volkerling AM; Ke YD; Delerue F; Ittner LM
    Acta Neuropathol; 2020 Sep; 140(3):279-294. PubMed ID: 32725265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.
    Barbero-Camps E; Fernández A; Martínez L; Fernández-Checa JC; Colell A
    Hum Mol Genet; 2013 Sep; 22(17):3460-76. PubMed ID: 23648430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.
    Caccamo A; Branca C; Talboom JS; Shaw DM; Turner D; Ma L; Messina A; Huang Z; Wu J; Oddo S
    J Neurosci; 2015 Oct; 35(41):14042-56. PubMed ID: 26468204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.